Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the 2025 Wells Fargo Healthcare Conference in Boston on September 5, the Morgan Stanley 23rd Annual Global Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference, both in New York on September 8. A webcast of the Wells Fargo presentation will be available on the company's website for 90 days after the event.
Ventyx Biosciences (Nasdaq: VTYX), azienda biofarmaceutica in fase clinica che sviluppa terapie orali per malattie autoimmuni, infiammatorie e neurodegenerative, ha comunicato la sua partecipazione a tre conferenze per investitori previste a settembre 2025.
La societ脿 presenter脿 al Wells Fargo Healthcare Conference 2025 a Boston il 5 settembre, al Morgan Stanley 23rd Annual Global Healthcare Conference e al H.C. Wainwright 27th Annual Global Investment Conference, entrambi a New York l'8 settembre. La presentazione al Wells Fargo sar脿 disponibile in webcast sul sito aziendale per 90 giorni dopo l'evento.
Ventyx Biosciences (Nasdaq: VTYX), una compa帽铆a biofarmac茅utica en fase cl铆nica que desarrolla terapias orales para enfermedades autoinmunes, inflamatorias y neurodegenerativas, ha anunciado su participaci贸n en tres conferencias para inversores en septiembre de 2025.
La empresa presentar谩 en la 2025 Wells Fargo Healthcare Conference en Boston el 5 de septiembre, y en la Morgan Stanley 23rd Annual Global Healthcare Conference y la H.C. Wainwright 27th Annual Global Investment Conference, ambas en Nueva York el 8 de septiembre. La presentaci贸n de Wells Fargo estar谩 disponible en webcast en la p谩gina web de la compa帽铆a durante 90 d铆as tras el evento.
Ventyx Biosciences (Nasdaq: VTYX)電� 鞛愱皜氅挫棴 歆堩櫂, 鞐检靹� 歆堩櫂 氚� 鞁犼步韲错枆靹� 歆堩櫂鞚� 鞙勴暅 瓴疥惮 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿�, 2025雲� 9鞗旍棎 臧滌禍霅橂姅 韴瀽鞛� 須岇潣 靹� 瓿踌棎 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 9鞗� 5鞚� 氤挫姢韯挫棎靹� 鞐措Μ電� 2025 Wells Fargo Healthcare Conference鞐愳劀 氚滍憸頃橂┌, 9鞗� 8鞚� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley 23rd Annual Global Healthcare Conference鞕赌 H.C. Wainwright 27th Annual Global Investment Conference鞐愳劀霃� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. Wells Fargo 氚滍憸電� 頄夓偓 頉� 90鞚缄皠 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Ventyx Biosciences (Nasdaq: VTYX), une soci茅t茅 biopharmaceutique en phase clinique qui d茅veloppe des traitements oraux pour les maladies auto-immunes, inflammatoires et neurod茅g茅n茅ratives, a annonc茅 sa participation 脿 trois conf茅rences pour investisseurs en septembre 2025.
La soci茅t茅 pr茅sentera lors de la 2025 Wells Fargo Healthcare Conference 脿 Boston le 5 septembre, ainsi qu'脿 la Morgan Stanley 23rd Annual Global Healthcare Conference et 脿 la H.C. Wainwright 27th Annual Global Investment Conference, toutes deux 脿 New York le 8 septembre. La pr茅sentation 脿 Wells Fargo sera disponible en webcast sur le site de la soci茅t茅 pendant 90 jours apr猫s l'茅v茅nement.
Ventyx Biosciences (Nasdaq: VTYX), ein biopharmazeutisches Unternehmen in klinischer Phase, das orale Therapien f眉r Autoimmun-, entz眉ndliche und neurodegenerative Erkrankungen entwickelt, hat seine Teilnahme an drei Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird am 2025 Wells Fargo Healthcare Conference in Boston am 5. September sowie am Morgan Stanley 23rd Annual Global Healthcare Conference und am H.C. Wainwright 27th Annual Global Investment Conference, beide am 8. September in New York, pr盲sentieren. Die Wells-Fargo-Pr盲sentation wird als Webinar f眉r 90 Tage nach der Veranstaltung auf der Unternehmenswebsite verf眉gbar sein.
- None.
- None.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (鈥淰entyx鈥�, 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences:
- 2025 Wells Fargo Healthcare Conference
Location: Boston, MA
Date: Friday, September 5, 2025
Time: 11:00-11:35 AM EDT
- Morgan Stanley 23rd Annual Global Healthcare Conference
Location: New York, NY
Date: Monday, September 8, 2025
- H.C. Wainwright 27th Annual Global Investment Conference
Location: New York, NY
Date: Monday, September 8, 2025
A webcast of the Wells Fargo presentation will be available in the Investors and News section of the Ventyx website at聽. A webcast replay will also be available on this website shortly after conclusion of the event for 90 days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.
Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that completed a Phase 2a study in Parkinson鈥檚 disease and is in Phase 2 development for cardiometabolic disease. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor.
For more information on Ventyx, please visit our website at聽.
Investor Relations Contact:
Alex Schwartz
Vice President, Investor Relations and FP&A
Ventyx Biosciences, Inc.
FAQ
When is Ventyx Biosciences (VTYX) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Ventyx Biosciences' (VTYX) Wells Fargo conference presentation?
Which investor conferences is Ventyx Biosciences (VTYX) attending in September 2025?
What type of therapies is Ventyx Biosciences (VTYX) developing?
